UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Economic Evaluation of Apixaban for the Prevention of Stroke in Atrial Fibrillation in the Netherlands

Value in health, 2013-11, Vol.16 (7), p.A529-A530

2013

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Value in health, 2013-11, Vol.16 (7), p.A441-A441

2013

Link zum Volltext

Verfügbarkeit prüfen

EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands

Value in health, 2023-12, Vol.26 (12), p.S110

2023

Link zum Volltext

Verfügbarkeit prüfen

PCN68 Pharmacoeconomic Evaluation of Rituximab as Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Real-World Population Based Study

Value in health, 2012-11, Vol.15 (7), p.A421-A421

2012

Link zum Volltext

Verfügbarkeit prüfen

PMS49 Cost-Effectiveness of Rituximab in the Treatment of RA Patients in the Netherlands

Value in health, 2011, Vol.14 (7), p.A311-A311

2011

Link zum Volltext

Verfügbarkeit prüfen

EE302 Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma (uMPM) in the Netherlands

Value in health, 2022-12, Vol.25 (12), p.S113-S113

2022

Link zum Volltext

Verfügbarkeit prüfen

PMS6 A Network Meta-analysis of Biologic Treatments in TNF-IR Rheumatoid Arthritis Patients

Value in health, 2011, Vol.14 (7), p.A303-A303

2011

Link zum Volltext

Verfügbarkeit prüfen

EE383 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Nivolumab Monotherapy (NIVO) for Patients With Advanced Melanoma in the Netherlands

Value in health, 2023-12, Vol.26 (12), p.S124

2023

Link zum Volltext

Verfügbarkeit prüfen

PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

Value in health, 2018-10, Vol.21, p.S46-S46

2018

Link zum Volltext

Verfügbarkeit prüfen

PCV103 - Economic Evaluation of Apixaban for the Prevention of Stroke in Atrial Fibrillation in the Netherlands

Value in health, 2013-11, Vol.16 (7), p.A529-A530

2013

Link zum Volltext

Verfügbarkeit prüfen

PDB57 - Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Value in health, 2013-11, Vol.16 (7), p.A441-A441

2013

Link zum Volltext

Verfügbarkeit prüfen

PCN109 COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING

Value in health, 2009, Vol.12 (7), p.A277-A277

2009

Link zum Volltext

Verfügbarkeit prüfen

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

Value in health, 2006-11, Vol.9 (6), p.A203-A203

2006

Link zum Volltext

Verfügbarkeit prüfen

MD2 ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS

Value in health, 2007, Vol.10 (6), p.A235-A236

2007

Link zum Volltext

Verfügbarkeit prüfen

Airway epithelial cell mediators induce differentiation of an immature mast cell line

Immunology letters, 1997-05, Vol.56 (1-3), p.155

Pompen, M

1997

Link zum Volltext

Verfügbarkeit prüfen

PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

Value in health, 2008, Vol.11 (6), p.A472-A472

2008

Link zum Volltext

Verfügbarkeit prüfen

MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

Value in health, 2008, Vol.11 (6), p.A347-A347

2008

Link zum Volltext

Verfügbarkeit prüfen

PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

Value in health, 2005-11, Vol.8 (6), p.A118-A118

2005

Link zum Volltext

Verfügbarkeit prüfen

Lung epithelial H292 cells induce differentiation of immature human HMC-1 mast cells by interleukin-6 and stem cell factor

Clinical and experimental allergy, 2000-08, Vol.30 (8), p.1104-1112

2000

Link zum Volltext

Verfügbarkeit prüfen

Products from human mast cell line cells enhance the production of interferon‐γ by CD8+ and CD4+ T cells

Immunology, 2002-05, Vol.106 (1), p.11-19

2002

Link zum Volltext

Verfügbarkeit prüfen

Products from human mast cell line cells enhance the production of interferon- gamma by CD8 super(+) and CD4 super(+) T cells

Immunology, 2002-05, Vol.106 (1), p.11-19

2002

Link zum Volltext

Verfügbarkeit prüfen

Airway epithelial cell mediators induce differentiation of an immature mast cell line

Immunology letters, 1997-05, Vol.56, p.155-155

1997

Link zum Volltext

Verfügbarkeit prüfen

Products from mast cells influence T lymphocyte proliferation and cytokine production—relevant to allergic asthma?

Immunology letters, 1997-06, Vol.57 (1), p.47-51

1997

Link zum Volltext

Verfügbarkeit prüfen

Mediators produced by airway epithelial cells influence proliferation and differentiation of immature mast cells

International archives of allergy and immunology, 1997-01, Vol.113 (1-3), p.363

1997

Link zum Volltext

Verfügbarkeit prüfen

Activated human mast cells (HMC-1) inhibit proliferation but increase IFN-γ production by CD8 + T cells

Immunology letters, 1997-05, Vol.56, p.35-36

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(43)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Internal Medicine
(12)
Humans
(11)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Immunology
(5)
Old Medline
(4)
Allergy
(3)
Biological And Medical Sciences
(3)
Cd8-Positive T-Lymphocytes - Immunology
(3)
Cytokines - Biosynthesis
(3)
Female
(3)
Mast Cells
(3)
Mast Cells - Physiology
(3)
Netherlands
(3)
Quality-Adjusted Life Years
(3)
Adrenocorticotropic Hormone
(2)
Adult
(2)
Aged
(2)
Aids/hiv
(2)
Animals
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Economic Evaluation of Apixaban for the Prevention of Stroke in Atrial Fibrillation in the Netherlands

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands

PCN68 Pharmacoeconomic Evaluation of Rituximab as Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Real-World Population Based Study

PMS49 Cost-Effectiveness of Rituximab in the Treatment of RA Patients in the Netherlands

EE302 Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma (uMPM) in the Netherlands

PMS6 A Network Meta-analysis of Biologic Treatments in TNF-IR Rheumatoid Arthritis Patients

EE383 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Nivolumab Monotherapy (NIVO) for Patients With Advanced Melanoma in the Netherlands

PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

PCV103 - Economic Evaluation of Apixaban for the Prevention of Stroke in Atrial Fibrillation in the Netherlands

PDB57 - Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

PCN109 COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

MD2 ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS

Airway epithelial cell mediators induce differentiation of an immature mast cell line

PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

Lung epithelial H292 cells induce differentiation of immature human HMC-1 mast cells by interleukin-6 and stem cell factor

Products from human mast cell line cells enhance the production of interferon‐γ by CD8+ and CD4+ T cells

Products from human mast cell line cells enhance the production of interferon- gamma by CD8 super(+) and CD4 super(+) T cells

Airway epithelial cell mediators induce differentiation of an immature mast cell line

Products from mast cells influence T lymphocyte proliferation and cytokine production—relevant to allergic asthma?

Mediators produced by airway epithelial cells influence proliferation and differentiation of immature mast cells

Activated human mast cells (HMC-1) inhibit proliferation but increase IFN-γ production by CD8 + T cells

Suchergebnisse filtern